Publications by authors named "John Bothos"

Claim this Profile
A
A phase 1 study of durvalumab as monotherapy or combined with tremelimumab with or without azacitidine in patients with myelodysplastic syndrome.
Guillermo Garcia-Manero, Manila Gaddh, Uwe Platzbecker, R Coleman Lindsley, Sarah M Larson, John Bothos

Ann Hematol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons, John Bothos

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Roy S Herbst, Margarita Majem, Fabrice Barlesi, Enric Carcereny, Quincy Chu, John Bothos

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
Johann S de Bono, Mark T Fleming, Judy S Wang, Richard Cathomas, Manuel Selvi Miralles, John Bothos

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Martin Dreyling, Wojciech Jurczak, Mats Jerkeman, Rodrigo Santucci Silva, Chiara Rusconi, John Bothos

Lancet· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Ravi Salgia, Premal Patel, John Bothos, Wei Yu, Steve Eppler

Clin Cancer Res· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Yan Xin, Denise Jin, Stephen Eppler, Lisa A Damico-Beyer, Amita Joshi, John Bothos

J Clin Pharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective in mitotic arrest 1/ring finger 8 is a checkpoint protein that antagonizes the human mitotic exit network.
Robyn L Tuttle, John Bothos, Matthew K Summers, Francis C Luca, Thanos D Halazonetis

Mol Cancer Res· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human LATS1 is a mitotic exit network kinase.
John Bothos, Robyn L Tuttle, Michelle Ottey, Francis C Luca, Thanos D Halazonetis

Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CHFR mitotic checkpoint protein delays cell cycle progression by excluding Cyclin B1 from the nucleus.
Matthew K Summers, John Bothos, Thanos D Halazonetis

Oncogene· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer.
George Mariatos, John Bothos, Panayotis Zacharatos, Matthew K Summers, Daniel M Scolnick

Cancer Res· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Chfr mitotic checkpoint protein functions with Ubc13-Mms2 to form Lys63-linked polyubiquitin chains.
John Bothos, Matthew K Summers, Monica Venere, Daniel M Scolnick, Thanos D Halazonetis

Oncogene· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Crystal structure of a human Mob1 protein: toward understanding Mob-regulated cell cycle pathways.
Elena S Stavridi, Kimberly G Harris, Yentram Huyen, John Bothos, Peter-Mark Verwoerd

Structure· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis